Santander, Spain: Subjects with a history of cannabis use are less likely than abstainers to develop non-alcoholic fatty liver disease (NAFLD), according to longitudinal data published in the journal Progress in Neuro-Psychopharmacology and Biological Psychiatry.
A team of Spanish investigators assessed the relationship between cannabis use and liver steatosis over a three-year period. They determined that those subjects “who reported continuing cannabis use were at lower risk for developing NAFLD.”
They concluded: “Our results suggest that using cannabis could have a protective effect on liver steatosis. The beneficial effect of cannabis at the level of the development of steatosis seems to be secondary to its modulation effect on weight gain and the reduced development of obesity. … These results are in line with previous studies in the general population, in which cannabis showed significantly lower NAFLD prevalence compared to non-users.”
For more information, contact Paul Armentano, NORML Deputy Director. Full text of the study, “Cannabis consumption and non-alcoholic fatty liver disease: A three years longitudinal study in first episode non-affective psychosis patients,” appears in Progress in Neuro-Psychopharmacology and Biological Psychiatry.